# JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

> **NCT06846437** · PHASE3 · RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 228 (estimated)

## Conditions studied

- Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

## Interventions

- **DRUG:** JSKN003
- **DRUG:** Trastuzumab emtansine (T-DM1)

## Key facts

- **NCT ID:** NCT06846437
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2026-10-13
- **Final completion:** 2028-12-31
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846437, "JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06846437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*